Neurotrope (NTRP) began trading on the NASDAQ Stock Market this week, successfully achieving an uplist from the OTC.
The company is focused on developing new therapies for the treatment of neurodegenerative diseases and developmental disorders. The science centers on a group of molecules called bryostatins, which were first isolated 50 years ago from marine invertebrates called bryozoans.
According to Chemical & Engineering News, bryostatins were hailed as key compounds in the fight against cancer, but over the years, Bryostatin 1, the most-studied member of the family, yielded mostly mediocre results, both on its own and in combinations with other drugs. Additionally, harvesting them from the naturally occurring bryozoan is impractical, and their long chemical syntheses were too unwieldy for drugmakers. Several years ago, however, tests in animals indicated that Bryostatin 1 enhances memory and could be used to treat Alzheimer’s disease and strokes.
The company has been conducting a Phase 2 study with Bryostatin 1 in 148 moderate to severe Alzheimer’s dementia patients since January 2016 and expects to announce top line efficacy results next month. Followers of Alzheimer’s research will know that the FDA hasn’t approved a new medication in 14 years. Countless companies have spent billions in research without success. Neurotrope opened the NASDAQ this morning to commemorate its uplisting, and we hope that all of us will be able to cheer the upcoming clinical results.
Source: The NASDAQ Stock Market
Please email us at [email protected] if you are a Public Company and would like to see our Testimonials.
Please click here if you would like information on our new trading platform.
Please click here if you’re an investor and would like to see our weekly newsletter.
Read Next
